XML 42 R29.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Other Income and Expenses, Net | 12 Months Ended
--- | ---
Dec. 31, 2021
Other Income And Expenses [Abstract] |
Other Income and Expenses, Net |
| 2 1. | OTHER INCOME AND EXPENSES, NET
Other income and expenses, net consisted of the following:
|  | Year ended December 31, 2021 |  |  | Year ended December 31, 2020 |  |  | Year ended December 31, 2019 |
Public funding |  |  | 162 |  |  |  | 231 |  |  |  | 132 |
Phase-out and start-up costs |  |  | — |  |  |  | (8 | ) |  |  | (38 | )
Exchange gains and losses, net |  |  | 7 |  |  |  | 8 |  |  |  | — |
Patent costs |  |  | (10 | ) |  |  | (11 | ) |  |  | (1 | )
Gain on sale of non-current assets |  |  | 5 |  |  |  | 14 |  |  |  | 7 |
COVID-19 incremental costs |  |  | (19 | ) |  |  | (32 | ) |  |  | — |
Other, net |  |  | (4 | ) |  |  | — |  |  |  | 3 |
Total |  |  | 141 |  |  |  | 202 |  |  |  | 103 |
The Company receives significant public funding from governmental agencies in several jurisdictions. Public funding for research, development and other innovation programs is recognized ratably as the related costs are incurred once the agreement with the respective governmental agency has been signed and all applicable conditions have been met. Public funding received in the year ended December 31, 2017 from the Nano2017 program with the French government is subject to a financial return in the year 2024 and depends on the future cumulative sales of a certain product group over a five-year period. As such, the criteria for recognizing the grant income are not met. As at December 31, 2021, an amount of $44 million, corresponding primarily to the Nano2017 program, was reported as a liability in the consolidated balance sheet, compared to an amount of $42 million as at December 31, 20 20. The Company also participates in the European Commission's Important Projects of Common Interests (IPCEI), until 2022 in France and until 2024 in Italy. For the latter, the Company reported $195 million receivables, of which $111 million reported on the line "Other current assets" in the consolidated balance sheet for the year ended December 31, 2021, compared to $206 million receivables, of which $105 million reported on the line "Other current assets" in the consolidated balance sheet for the year ended December 31, 2020. Start-up costs represent costs incurred in the start-up and testing of the Company’s new manufacturing facilities, before reaching the earlier of a minimum level of production or six months after the fabrication line’s quality certification. Phase-out costs are costs incurred during the closing stage of a Company’s manufacturing facility. They are treated in the same manner as start-up costs. Exchange gains and losses, net represent the portion of exchange rate changes on transactions denominated in currencies other than an entity’s functional currency and the changes in fair value of derivative instruments which are not designated as hedges and which have a cash flow effect related to operating transactions, as described in Note 28. Patent costs mainly include legal and attorney fees and payment for claims, patent pre-litigation consultancy and legal fees. They are reported net of settlements, if any, which primarily include reimbursements of prior patent litigation costs. COVID-19 incremental costs are mainly composed of purchases of medical disposables, such as masks and sanitizers, and other expenses related to sanitary measures undertaken to protect employees during the global outbreak of COVID-19.

X
- References No definition available. + Details
Name: | us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -URI http://asc.fasb.org/topic&trid=2122503 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 610 -URI http://asc.fasb.org/topic&trid=49130413 + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration